---
title: "Arrow Pharmaceuticals soars 22% on strong Phase 3 lipid drug results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293511229.md"
description: "Arrow Pharma jumps 22% as Phase 3 data shows 79-81% triglyceride drop; FDA filing planned for late 2026."
datetime: "2026-07-22T19:13:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293511229.md)
  - [en](https://longbridge.com/en/news/293511229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293511229.md)
generator: "portal-rs"
---

# Arrow Pharmaceuticals soars 22% on strong Phase 3 lipid drug results

箭头制药 (ARWR.US) 盘中涨**21.85%**，现报**90.80 美元**。

plozasiran 降脂药三期试验显示强效，甘油三酯水平降低 79-81%，安全性良好。公司计划 2026 年底向 FDA 提交补充新药申请。

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [Can Arrowhead Pharmaceuticals (ARWR) Still Look Like A Bargain Following Its Phase 3 SHASTA Data?](https://longbridge.com/en/news/298165580.md)
- [Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales](https://longbridge.com/en/news/298117407.md)
- [Public Employees Retirement System of Ohio Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR](https://longbridge.com/en/news/298105697.md)
- [Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/297869579.md)
- [Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials](https://longbridge.com/en/news/297536982.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**